Core Viewpoint - The article discusses the strategic investment actions taken by Jinbo Biological, including a directed share issuance to Yangshengtang and a share transfer to Hangzhou Jiushi, totaling 3.4 billion yuan, which positions the company for growth in the recombinant collagen market [1][2][3]. Strategic Investment - Jinbo Biological plans to issue up to 7.1756 million shares at a price of 278.72 yuan per share, raising a maximum of 2 billion yuan, with 1.15 billion yuan allocated for the development of a humanized collagen FAST database and product platform [5]. - Following the transactions, Yangshengtang will become the second-largest shareholder of Jinbo Biological, holding over 5% of the shares, while the actual controller Yang Xia's stake will decrease to 50.73% [7]. Technological Strength - Jinbo Biological is recognized for its technological capabilities, being the first A-share company to focus on recombinant collagen, achieving significant breakthroughs in the field of biomaterials [10]. - The company has received approval for its third type of recombinant humanized collagen medical device, indicating its strong position in the market [10]. - Projected revenues for 2024 are 1.443 billion yuan, representing an 84.92% year-on-year increase, with a net profit of 732 million yuan, up 144.27%, and a gross margin of 92.02% [10]. Market Dynamics - The investment by Zhong Shanshan is seen as a strategic move to address the stagnation in the performance of his other companies, with the recombinant collagen market expected to grow significantly, reaching 58.57 billion yuan by 2025 and over 219.38 billion yuan by 2030 [12][13]. - The collaboration between Jinbo Biological and Yangshengtang is expected to enhance production capabilities and market reach, leveraging Yangshengtang's established distribution networks [15][17]. Industry Changes - The partnership is set to reshape the competitive landscape, with recombinant collagen emerging as a high-growth segment amid increasing competition [19]. - Jinbo Biological aims to transition from a technology leader to a market leader, supported by the strategic investment and anticipated product launches [19][20].
中国前首富，34亿元入局